TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants

Tuesday, January 16, 2024

ExeVir Bio, a biotechnology company focused on developing potent heavy chain-only antibody therapies for broad protection against infectious diseases, has recently presented new findings demonstrating the high efficacy of its antibodies in neutralizing the current COVID-19 Omicron variants.

In contrast to authorized SARS-CoV-2 therapeutic antibodies used in clinical applications, which have shown significant reduction or complete loss of virus neutralization against current variants, ExeVir's XVR012, comprising XVR013m and XVR014, stands out. This innovative combination targets three distinct epitopes highly conserved across the broad sarbecovirus subgenus of Coronaviridae, minimizing the risk of viral escape. XVR013m is a heavy chain-only antibody targeting a unique membrane-proximal epitope in the S2 subunit of the spike protein, while XVR014 is a bispecific heavy chain-only antibody complementing XVR013m by targeting two epitopes in the receptor-binding domain of the S1 subunit of the spike protein. Notably, both XVR013m and XVR014 neutralize both SARS-CoV-1 and SARS-CoV-2 viruses.

The XVR012 cocktail demonstrates exceptional neutralization potency, displaying an IC50 range of 0.8 to 1.8 ng/mL (pseudovirus neutralization assay) against all evaluated SARS-CoV-2 variants, including the prevalent E.G.5.1, HV.1, and BA.2.86.1. Ongoing testing is being conducted to assess its effectiveness against newly emerging variants.

ExeVir is gearing up for the clinical development of both the combination XVR012 and its individual components, XVR013m and XVR014.

Dr. Torsten Mummenbrauer, CEO of ExeVir, highlighted the ongoing threat of COVID-19, particularly for immunocompromised patients and the elderly, constituting around 4% and 10% of the world population, respectively. Despite the availability of vaccines, these populations remain at high risk of severe COVID-19. Dr. Mummenbrauer emphasized the unique and potent approach of XVR012, targeting three highly conserved epitopes in the SARS-CoV-2 spike protein. He expressed confidence that this cocktail could prove effective against virtually all currently circulating variants, including the challenging EG.5.1, HV.1, and BA.2.86.1. The data underscores the potential of ExeVir's antibodies in addressing the ongoing challenges posed by new Omicron variants.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit